CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on November 14, 2007
Clinical Journal of the American Society of Nephrology
© 2007 American Society of Nephrology
doi: 10.2215/CJN.02490607
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.02490607v1
3/1/139    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrade, J.
Right arrow Articles by Sirrs, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrade, J.
Right arrow Articles by Sirrs, S.

Received June 15, 2007
Accepted on September 12, 2007

ORIGINAL ARTICLES

Screening for Fabry Disease in Patients with Chronic Kidney Disease: Limitations of Plasma {alpha}-Galactosidase Assay as a Screening Test

Jason Andrade *, Paula J. Waters {dagger}, R. Suneet Singh *{ddagger}, Adeera Levin *{ddagger}, Bee-Chin Toh {dagger}, Hilary D. Vallance {dagger}, and Sandra Sirrs *{sect}1

Departments of *Medicine, and {dagger}Pathology and Laboratory Medicine and Divisions of, {ddagger}Nephrology, and {sect}Endocrinology, University of British Columbia, Vancouver, British Columbia, Canada


1 To whom correspondence should be addressed. E-mail: sandra.sirrs{at}vch.ca.


  Abstract

Background and objectives: Fabry disease is a progressive X-linked disorder of glycosphingolipid metabolism that typically presents in childhood and progresses to heart failure and renal failure in adulthood. This study sought to determine the prevalence of Fabry disease in a multiethnic male chronic kidney disease population, involving dialysis-dependent, non–dialysis-dependent, and transplant patients.

Design, setting, participants, & measurements: A total of 499 patients were screened with assay of {alpha}-galactosidase activity using fluorometric enzyme assay on plasma prepared from fresh heparinized blood, followed by leukocyte {alpha}-galactosidase activity in the subset of patients with plasma {alpha}-galactosidase activity below the second percentile (corresponding to a value <3.0 nmol/h per ml plasma).

Results: This study did not identify any new cases of Fabry disease; however, repeat testing of some of the study patients identified three limitations of the plasma enzyme assay that is commonly used as a high throughput screening method for Fabry disease: (1) False-negative results can occur; (2) these false-negative results are not prevented by use of inhibitors of {alpha}-galactosidase B activity; and (3) considerable intraindividual variation in plasma {alpha}-galactosidase levels reduces the discriminatory power of the screening test.

Conclusion: Clinicians need to be aware that screening using plasma will fail to detect some patients with Fabry disease.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
B. Oqvist, B. M. Brenner, J. P. Oliveira, A. Ortiz, R. Schaefer, E. Svarstad, C. Wanner, K. Zhang, and D. G. Warnock
Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1736 - 1743.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. D. Schoenmakere, B. Poppe, B. Wuyts, K. Claes, D. Cassiman, B. Maes, D. Verbeelen, R. Vanholder, D. R. Kuypers, N. Lameire, et al.
Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients
Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4044 - 4048.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Society of Nephrology.